Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 19/20 | 0.38 |
| ▸ | RARB | P10826 | 19/20 | 0.38 |
| ▸ | RARG | P13631 | 18/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292555 | 1.00 | RARA (0.38) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6761156 | 0.86 | — | — | |
| SCHEMBL6297168 | 0.83 | RARA (0.40) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6294125 | 0.82 | HPGD (0.47) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6292573 | 0.80 | RARB (0.50) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6292700 | 0.76 | RARA (0.44) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8563491 | 0.75 | RARA (0.31) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8772575 | 0.74 | RARA (0.68) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6294021 | 0.74 | RARA (0.69) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6294022 | 0.74 | RARA (0.69) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010000511-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2001-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000511-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.